Ticagrelor + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)

Trial Timeline

Sep 1, 2011 → Nov 1, 2013

NCT ID

NCT01347580

About Ticagrelor + Placebo

Ticagrelor + Placebo is a approved stage product being developed by AstraZeneca for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT01347580. Target conditions include Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI).

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction were approved

Approved (20) Terminated (4) Active (0)

✅AbciximabEli LillyApproved

✅abciximabEli LillyApproved

✅Ticagrelor + ClopidogrelAstraZenecaApproved

✅ticagrelor + aspirinAstraZenecaApproved

✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

✅clopidogrel and metoprololAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03615924	Phase 3	Terminated	Sep 26, 2018	Aug 13, 2020	Sickle Cell Disease
NCT03354429	Phase 3	Completed	Jan 22, 2018	Dec 13, 2019	Acute Ischaemic Stroke
NCT02482298	Phase 2	Completed	Jul 9, 2015	Nov 16, 2016	Sickle Cell Disease
NCT02352402	Phase 3	UNKNOWN	Mar 1, 2015	Aug 1, 2020	Coronary Artery Disease
NCT02110303	Phase 2/3	Completed	Mar 1, 2015	Apr 1, 2018	Coronary Artery Disease
NCT02335099	Phase 1/2	Completed	Dec 1, 2014	Jun 1, 2019	End Stage Renal Disease
NCT01998399	Phase 2	Terminated	Aug 1, 2014	Dec 1, 2015	Community Acquired Pneumonia, Severe
NCT02070653	Phase 2	Completed	Mar 1, 2014	Jul 1, 2017	Abdominal Aortic Aneurysm
NCT01347580	Approved	Completed	Sep 1, 2011	Nov 1, 2013	Myocardial Infarction

Competing Products

20 competing products in Myocardial Infarction

See all competitors

Product	Company	Stage	Hype Score
Butylphthalide + Butylphthalide placebo	CSPC Pharmaceutical Group Limited	Phase 3	47
Abciximab	Eli Lilly	Approved	43
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 3	40
Regadenoson + gadofoveset trisodium	Astellas Pharma	Phase 2	35
Half-dose of the Tc99-m sestamibi (Cardiolite)	Astellas Pharma	Pre-clinical	18
No intervention	Astellas Pharma	Pre-clinical	22
Empagliflozin + Placebo	Eli Lilly	Phase 3	40
Abciximab + Abciximab placebo	Eli Lilly	Phase 3	36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serum	Eli Lilly	Phase 3	40
Abciximab	Eli Lilly	Approved	43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab	Eli Lilly	Phase 3	40
fibrinolytic therapy or combination reduced fibrinolytic therapy	Eli Lilly	Phase 3	40
abciximab	Eli Lilly	Approved	43
tenecteplase + enoxaparin + clopidogrel	Eli Lilly	Phase 2/3	38
Thrombolytic therapy	Eli Lilly	Pre-clinical	22
Ticagrelor	AstraZeneca	Pre-clinical	26
Ticagrelor	AstraZeneca	Phase 2	31
Dual-antiplatelet therapy + Dual-antiplatelet therapy	AstraZeneca	Pre-clinical	22
Metoprolol- Toprol XL + Metoprolol- Lopressor	AstraZeneca	Phase 1	29
Ticagrelor orodispersible tablets + Ticagrelor standard tablets	AstraZeneca	Phase 3	40